The present invention relates to therapeutic combinations of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-2-cyclopentene- 1-methanol (1592U89), 3'-azido-3'-deoxythymidine (zidovudine) and (2R,cis)-4-amino-]-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin- 2-one (3TC) (or, alternatively to 3TC, (2R,cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyr imidin-2-one (FTC)) which have anti-HIV activity. The present invention is also concerned with pharmaceutical compositions containing said combinations and their use in the treatment of HIV infections including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors.

A invenção atual relaciona-se às combinações therapeutic de (1S, 4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-2-cyclopentene- 1-methanol (1592U89), 3'-azido-3'-deoxythymidine (zidovudine) e (2R, cis)-4-amino-]-1-(2-hydroxymethyl-1, 3-oxathiolan-5-yl)-(1H)-pyrimidin- 2-one (3TC) (ou, alternativamente a 3TC, (2R, cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1, 3-oxathiolan-5-yl)-(1H)-pyr imidin-2-one (FTC)) que têm a atividade anti-Anti-HIV. A invenção atual é concernida também com as composições pharmaceutical que contêm combinações ditas e seu uso no tratamento de infecções de HIV including infecções com os mutants do HIV que carregam a resistência aos inibidores do nucleoside e/ou do non-non-nucleoside.